Claims for Patent: 10,047,116

Summary for Patent: 10,047,116

Title:	Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
Abstract:	The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
Inventor(s):	Morein; Bror (Uppsala, SE), Berenjian; Saideh (Uppsala, SE), Hu; Kafei (Uppsala, SE)
Assignee:	MX Adjuvac AB (Enkoping, SE)
Application Number:	14/349,142
Patent Claims:	1. Stable nanoparticles comprising cholesterol and saponin quillaja saponin fraction QHC from Quillaha saponaria Molina, wherein the nanoparticles do not comprise a phospholipid and have a particle diameter in the range of 17-20 nanometers wherein the molar ratio between cholesterol and quillaja saponin is from 1:2 to 2:1. 2. The nanoparticles according to claim 1, further comprising at least one of an amphipathic or a hydrophobic molecule. 3. Nanoparticles according to claim 2, wherein the amphipathic or hydrophobic molecule is at least one member selected from an antigen, an adjuvant, a targeting molecule, a pharmaceutical compound and a food related compound. 4. A composition comprising a first plurality of nanoparticles according to claim 1 and a second plurality of nanoparticles comprising cholesterol and a component from Quillaha saponaria Molina selected from quillaja acid and quillaja saponin, wherein the second plurality of nanoparticles do not comprise a phospholipid. 5. The composition according to claim 4, wherein the first plurality of nanoparticles and the second plurality nanoparticles comprise different quillaja saponin fractions. 6. A pharmaceutical composition comprising nanoparticles according to claim 1 and further comprising pharmaceutically acceptable buffers, diluents excipients, adjuvants and/or carriers. 7. A composition according to claim 4, further comprising pharmaceutically acceptable buffers, diluents excipients, adjuvants and/or carriers. 8. The composition according to claim 7 further comprising a vaccine. 9. Nanoparticles according to claim 3, wherein the adjuvant is diterpene. 10. The pharmaceutical composition according to claim 6, wherein the adjuvant is diterpene. 11. The pharmaceutical composition according to claim 6, further comprising a vaccine. 12. The pharmaceutical composition according to claim 10, wherein the vaccine is a pandemic flu vaccine. 13. The pharmaceutical composition according to claim 10, wherein the vaccine is a seasonal influenza virus vaccine. 14. The pharmaceutical composition according to claim 10, wherein the vaccine is a pandemic influenza virus vaccine. 15. The pharmaceutical composition according to claim 10, wherein the vaccine is a vaccine against a biological weapon. 16. The pharmaceutical composition according to claim 6, further comprising at least one of an anticancer drug Komplettering Saideh, a platinum coordination compound, a taxane compound, a camptohtecin compounds, an anti-tumor vinca alkaloid, an anti-tumor nucleoside derivative, a nitrogen mustard or nitrosourea alkylating agent, an anti-tumor anthracycline derivative, a trastzumab, an anti-tumor podophyllotoxon derivative, an antimetabolite, a steroid, an inhibitor of a mammalian target of rapamycin (mTOR), an agent for treating cancer, Cytarabin, Daunorubicin, Paclitaxel, Docetaxel, Cabazitaxel, Toricsel, and Trabectidin. 17. The nanoparticles according to claim 3, wherein the amphipathic or hydrophobic molecule is an adjuvant. 18. The nanoparticles according to claim 17, further comprising a vaccine. 19. The nanoparticles according to claim 3, wherein the amphipathic or hydrophobic molecule is chosen from Diterpenoid (DT), VLX40, Busulfan, roscovitine and vitamin D3.

Details for Patent 10,047,116

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	11/03/1998		2040-01-30
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	12/09/1999		2040-01-30
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	12/23/1909		2040-01-30
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	05/09/2011		2040-01-30
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	06/07/2013		2040-01-30
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	12/11/2014		2040-01-30